RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

My hunch is that corx has committed to negotiations regarding the outlicensing of CX1739 for any and all indications, but up-front for ADHD. As suggested in Varney's email on the subject, the delay in IND submission could be accounted for by such negotiations. Likewise, the silence on SA is consistent with an across-indications outlicensing of the compound.

If corx has the preclinical data to convince a counterparty that CX1739 has no toxicity problems, and if they can also provide animal data to confirm that the pharmacological profiles of CX717 and CX1739 are qualitatively the same, then an ADHD outlicencing shouldn't be a hard sell, since CX717 has already shown good efficacy in ADHD.

I think they are closing in on a deal with a company primarily interested in CX1739 in the treatment of ADHD, but are negotiating a deal for the molecule rather than the indication. My guess is that such a deal would raise $10-$15M.

What are the candidate companies for ADHD drug development?